▶Quinolones(ciprofloxacin)slightly increase the exposure to
rasagiline.oStudy
▶Reboxetineis predicted to increase the risk of a hypertensive
crisis when given withmonoamine-oxidase B inhibitors
(rasagiline, selegiline). Avoid.rTheoretical
▶Monoamine-oxidase B inhibitorsare predicted to increase the
risk of a hypertensive crisis when given with
sympathomimetics, inotropic. Avoid.rAnecdotal
▶Monoamine-oxidase B inhibitorsare predicted to increase the
risk of a hypertensive crisis when given with
sympathomimetics, vasoconstrictor. Avoid.rAnecdotal
Monoclonal antibodies→seeTABLE 15p. 850 (myelosuppression),
TABLE 12p. 850 (peripheral neuropathy),TABLE 9p. 849 (QT-interval
prolongation),TABLE 4p. 847 (antiplatelet effects)
adalimumab.alemtuzumab.atezolizumab.avelumab.basiliximab
.belimumab.benralizumab.bevacizumab.blinatumomab.
brentuximab vedotin.brodalumab.canakinumab.certolizumab
pegol.cetuximab.daratumumab.dupilumab.eculizumab.
elotuzumab.golimumab.guselkumab.infliximab.inotuzumab
ozogamicin.ipilimumab.ixekizumab.natalizumab.necitumumab
.nivolumab.obinutuzumab.ocrelizumab.ofatumumab.
olaratumab.panitumumab.pembrolizumab.pertuzumab.
ramucirumab.rituximab.sarilumab.secukinumab.siltuximab.
tocilizumab.trastuzumab.trastuzumab emtansine.ustekinumab.
vedolizumab..
▶Tocilizumabis predicted to decrease the exposure to
alprazolam. Monitor and adjust dose.oTheoretical
▶Blinatumomabis predicted to transiently increase the
exposure toaminophylline. Monitor and adjust dose.o
Theoretical
▶Sarilumabpotentially affects the exposure toaminophylline.
Monitor and adjust dose.oTheoretical
▶Tocilizumabis predicted to decrease the exposure to
aminophylline. Monitor and adjust dose.oTheoretical
▶Anthracyclinesare predicted to increase the risk of
cardiotoxicity when given withmonoclonal antibodies
(trastuzumab, trastuzumab emtansine). Avoid.r
Theoretical→Also seeTABLE 15p. 850
▶Antiarrhythmics(dronedarone)increase the risk of neutropenia
when given withbrentuximab vedotin. Monitor and adjust
dose.rTheoretical
▶Antiepileptics(carbamazepine)are predicted to decrease the
effects ofbrentuximab vedotin.rTheoretical
▶Tocilizumabis predicted to decrease the exposure to
antiepileptics(fosphenytoin, phenytoin). Monitor and adjust
dose.oTheoretical
▶Antifungals, azoles(itraconazole, ketoconazole)increase the risk
of neutropenia when given withbrentuximab vedotin. Monitor
and adjust dose.rStudy
▶Antifungals, azoles(itraconazole, ketoconazole, voriconazole)are
predicted to increase the exposure totrastuzumab emtansine.
Avoid.rTheoretical
▶Brentuximab vedotinincreases the risk of pulmonary toxicity
when given withbleomycin. Avoid.rStudy→Also see
TABLE 15p. 850
▶Tocilizumabis predicted to decrease the exposure tocalcium
channel blockers. Monitor and adjust dose.oTheoretical
▶Blinatumomabis predicted to transiently increase the
exposure tociclosporin. Monitor and adjust dose.o
Theoretical
▶Sarilumabpotentially affects the exposure tociclosporin.
Monitor and adjust dose.oTheoretical
▶Tocilizumabis predicted to decrease the exposure to
ciclosporin. Monitor and adjust dose.oTheoretical
▶Cobicistatis predicted to increase the exposure totrastuzumab
emtansine. Avoid.rTheoretical
▶Sarilumabpotentially decreases the exposure tocombined
hormonal contraceptives.rTheoretical
▶Corticosteroids(betamethasone, deflazacort, dexamethasone,
hydrocortisone, methylprednisolone, prednisolone, prednisone)
are predicted to decrease the efficacy ofmonoclonal antibodies
(atezolizumab, ipilimumab, nivolumab, pembrolizumab). Use
with caution or avoid.rTheoretical
▶Tocilizumabis predicted to decrease the exposure to
corticosteroids(dexamethasone, methylprednisolone). Monitor
and adjust dose.oTheoretical
▶Blinatumomabis predicted to transiently increase the
exposure tocoumarins(warfarin). Monitor and adjust dose.
oTheoretical
▶Sarilumabpotentially affects the exposure tocoumarins
(warfarin). Monitor and adjust dose.rTheoretical
▶Tocilizumabis predicted to decrease the exposure tocoumarins
(warfarin). Monitor and adjust dose.oTheoretical
▶Tocilizumabis predicted to decrease the exposure todiazepam.
Monitor and adjust dose.oTheoretical
▶HIV-protease inhibitors(lopinavir, ritonavir, saquinavir)are
predicted to increase the risk of neutropenia when given with
brentuximab vedotin. Monitor and adjust dose.rStudy
▶HIV-protease inhibitorsare predicted to increase the exposure
totrastuzumab emtansine. Avoid.rTheoretical
▶Idelalisibis predicted to increase the exposure totrastuzumab
emtansine. Avoid.rTheoretical→Also seeTABLE 15p. 850
▶Live vaccinesare predicted to increase the risk of generalised
infection (possibly life-threatening) when given with
monoclonal antibodies. Public Health England advises avoid
(refer to Green Book).rTheoretical
▶Macrolides(clarithromycin)increase the risk of neutropenia
when given withbrentuximab vedotin. Monitor and adjust
dose.rTheoretical
▶Macrolides(clarithromycin)are predicted to increase the
exposure totrastuzumab emtansine. Avoid.rTheoretical
▶Tocilizumabis predicted to decrease the exposure to
midazolam. Monitor and adjust dose.oTheoretical
▶Rifampicindecreases the effects ofbrentuximab vedotin.
rStudy
▶Sarilumabpotentially affects the exposure tosirolimus.
Monitor and adjust dose.oTheoretical
▶Sarilumabis predicted to decrease the exposure tostatins
(atorvastatin, simvastatin).oStudy
▶Tocilizumabis predicted to decrease the exposure tostatins
(atorvastatin, simvastatin). Monitor and adjust dose.o
Study
▶Sarilumabpotentially affects the exposure totacrolimus.
Monitor and adjust dose.oTheoretical
▶Blinatumomabis predicted to transiently increase the
exposure totheophylline. Monitor and adjust dose.o
Theoretical
▶Sarilumabpotentially affects the exposure totheophylline.
Monitor and adjust dose.oTheoretical
▶Tocilizumabis predicted to decrease the exposure to
theophylline. Monitor and adjust dose.oTheoretical
Montelukast
▶Antiepileptics(carbamazepine, fosphenytoin, phenobarbital,
phenytoin, primidone)are predicted to decrease the exposure
tomontelukast.nStudy
▶Clopidogrelis predicted to moderately increase the exposure
tomontelukast.oStudy
▶Enzalutamideis predicted to decrease the exposure to
montelukast.nStudy
▶Fibrates(gemfibrozil)are predicted to moderately increase the
exposure tomontelukast.oStudy
▶Leflunomideis predicted to increase the exposure to
montelukast.oTheoretical
▶Mitotaneis predicted to decrease the exposure tomontelukast.
nStudy
▶Opicaponeis predicted to increase the exposure to
montelukast. Avoid.oStudy
▶Rifampicinis predicted to decrease the exposure to
montelukast.nStudy
▶Teriflunomideis predicted to increase the exposure to
montelukast.oTheoretical
Morphine→see opioids
Moxifloxacin→see quinolones
Moxisylyte→seeTABLE 8p. 848 (hypotension)
Moxonidine→seeTABLE 8p. 848 (hypotension),TABLE 11p. 849 (CNS
depressant effects)BNFC 2018 – 2019 Monoamine-oxidase B inhibitors—Moxonidine 959
Interactions|Appendix 1A1